PL373465A1 - Kompozycje oparte na podstawionych pochodnych 1,3-difenyloprop-2-en-1-onu - Google Patents

Kompozycje oparte na podstawionych pochodnych 1,3-difenyloprop-2-en-1-onu

Info

Publication number
PL373465A1
PL373465A1 PL03373465A PL37346503A PL373465A1 PL 373465 A1 PL373465 A1 PL 373465A1 PL 03373465 A PL03373465 A PL 03373465A PL 37346503 A PL37346503 A PL 37346503A PL 373465 A1 PL373465 A1 PL 373465A1
Authority
PL
Poland
Prior art keywords
diphenylprop
derivatives
substituted
compositions based
diseases
Prior art date
Application number
PL03373465A
Other languages
English (en)
Other versions
PL207707B1 (pl
Inventor
Jamila Najib
Karine Caumont-Bertrand
Original Assignee
Genfit
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genfit filed Critical Genfit
Publication of PL373465A1 publication Critical patent/PL373465A1/pl
Publication of PL207707B1 publication Critical patent/PL207707B1/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/05—Phenols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/05—Phenols
    • A61K31/055—Phenols the aromatic ring being substituted by halogen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C323/00—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
    • C07C323/22—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and doubly-bound oxygen atoms bound to the same carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C323/00—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
    • C07C323/50—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton
    • C07C323/51—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton
    • C07C323/52—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being acyclic and saturated
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C59/40—Unsaturated compounds
    • C07C59/76—Unsaturated compounds containing keto groups
    • C07C59/90—Unsaturated compounds containing keto groups containing singly bound oxygen-containing groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C69/00—Esters of carboxylic acids; Esters of carbonic or haloformic acids
    • C07C69/66—Esters of carboxylic acids having esterified carboxylic groups bound to acyclic carbon atoms and having any of the groups OH, O—metal, —CHO, keto, ether, acyloxy, groups, groups, or in the acid moiety
    • C07C69/67—Esters of carboxylic acids having esterified carboxylic groups bound to acyclic carbon atoms and having any of the groups OH, O—metal, —CHO, keto, ether, acyloxy, groups, groups, or in the acid moiety of saturated acids
    • C07C69/708—Ethers
    • C07C69/712—Ethers the hydroxy group of the ester being etherified with a hydroxy compound having the hydroxy group bound to a carbon atom of a six-membered aromatic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C69/00—Esters of carboxylic acids; Esters of carbonic or haloformic acids
    • C07C69/66—Esters of carboxylic acids having esterified carboxylic groups bound to acyclic carbon atoms and having any of the groups OH, O—metal, —CHO, keto, ether, acyloxy, groups, groups, or in the acid moiety
    • C07C69/73—Esters of carboxylic acids having esterified carboxylic groups bound to acyclic carbon atoms and having any of the groups OH, O—metal, —CHO, keto, ether, acyloxy, groups, groups, or in the acid moiety of unsaturated acids
    • C07C69/738—Esters of keto-carboxylic acids or aldehydo-carboxylic acids

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Dermatology (AREA)
  • Pulmonology (AREA)
  • Endocrinology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Immunology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

Wynalazek dotyczy kompozycji zawierających pochodne 1,3-difenyloprop-2-en-1-onu przeznaczonych do zastosowania farmaceutycznego. Kompozycje według wynalazku są użyteczne szczególnie do zapobiegania albo leczenia chorób sercowo-naczyniowych, zespołu X, restenozy, cukrzycy, otyłości, nadciśnienia, chorób zapalnych, raków albo nowotworów (nowotworów łagodnych i guzów złośliwych), chorób neurodegeneracyjnych i dermatologicznych, oraz zaburzeń związanych ze stresem oksydacyjnym i na przykład starzeniem się skóry, w szczególności w kosmetyce (występowanie zmarszczek i podobnych).
PL373465A 2002-07-08 2003-07-08 Kompozycja do leczenia lub zapobiegania stanom patologicznym związanym ze stanami zapalnymi, neurodegeneracją, deregulacją metabolizmu lipidów i/lub glukozy, rozrostem komórek i/lub różnicowaniem komórek i/lub ze starzeniem się skóry lub ośrodkowego układu nerwowego PL207707B1 (pl)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR0208570A FR2841784B1 (fr) 2002-07-08 2002-07-08 Composition a base de derives de 1,3-diphenylprop-2en-1-one substitues, preparation et utilisations
PCT/FR2003/002128 WO2004005243A2 (fr) 2002-07-08 2003-07-08 Composition a base de derives de 1,3-diphenylprop-2-en-one substitues

Publications (2)

Publication Number Publication Date
PL373465A1 true PL373465A1 (pl) 2005-09-05
PL207707B1 PL207707B1 (pl) 2011-01-31

Family

ID=29725282

Family Applications (1)

Application Number Title Priority Date Filing Date
PL373465A PL207707B1 (pl) 2002-07-08 2003-07-08 Kompozycja do leczenia lub zapobiegania stanom patologicznym związanym ze stanami zapalnymi, neurodegeneracją, deregulacją metabolizmu lipidów i/lub glukozy, rozrostem komórek i/lub różnicowaniem komórek i/lub ze starzeniem się skóry lub ośrodkowego układu nerwowego

Country Status (24)

Country Link
US (3) US7632870B2 (pl)
EP (1) EP1519908B1 (pl)
JP (1) JP4907083B2 (pl)
KR (1) KR100947907B1 (pl)
CN (1) CN1688532B (pl)
AT (1) ATE364588T1 (pl)
AU (1) AU2003264699B2 (pl)
BR (1) BRPI0312399B8 (pl)
CA (1) CA2490993C (pl)
CY (1) CY1108051T1 (pl)
DE (1) DE60314420T2 (pl)
DK (1) DK1519908T3 (pl)
EA (1) EA012699B1 (pl)
ES (1) ES2287529T3 (pl)
FR (1) FR2841784B1 (pl)
IL (1) IL165454A (pl)
MX (1) MXPA05000425A (pl)
NO (1) NO334650B1 (pl)
NZ (1) NZ538052A (pl)
PL (1) PL207707B1 (pl)
PT (1) PT1519908E (pl)
SI (1) SI1519908T1 (pl)
WO (1) WO2004005243A2 (pl)
ZA (1) ZA200501081B (pl)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2841784B1 (fr) 2002-07-08 2007-03-02 Composition a base de derives de 1,3-diphenylprop-2en-1-one substitues, preparation et utilisations
FR2841900B1 (fr) * 2002-07-08 2007-03-02 Genfit S A Nouveaux derives de 1,3-diphenylprop-2-en-1-one substitues, preparation et utilisations
KR20060132903A (ko) * 2004-01-08 2006-12-22 장피트 1,3-디페닐프로프-2-엔-1-온 유도체 화합물, 그 제조방법및 용도
ZA200707427B (en) 2005-03-11 2008-11-26 Florey Howard Inst Flavonoid compounds and uses thereof
EP2641596B1 (en) 2009-11-26 2018-05-02 Genfit Use of 1,3-diphenylprop-2-en-1-one derivatives for treating liver disorders
WO2011080276A1 (en) 2009-12-29 2011-07-07 Genfit Pharmaceutical combinations comprising a dpp-4 inhibitor and a 1,3-diphenylprop-2-en-1-one derivative
EP2593426B1 (en) * 2010-07-12 2014-08-20 F.Hoffmann-La Roche Ag 1-hydroxyimino-3-phenyl-propanes
RU2631597C2 (ru) 2011-07-15 2017-09-25 Нусерт Сайенсиз, Инк. Композиции и способы модулирования метаболических путей
RU2014119220A (ru) * 2011-10-26 2015-12-10 Ф. Хоффманн-Ля Рош Аг 1-циклоалкил-или 1-гетероциклил-гидроксиимино-3-фенилпропаны
US9198454B2 (en) 2012-03-08 2015-12-01 Nusirt Sciences, Inc. Compositions, methods, and kits for regulating energy metabolism
EP2919772B1 (en) 2012-11-13 2019-03-27 NuSirt Sciences, Inc. Pde5 inhibitors and leucine or a leucine metabolite for use in the treatment of diabetes
PL2948137T3 (pl) * 2013-01-18 2019-02-28 Genfit Sposoby leczenia zwłóknienia i nowotworów
CA2902879C (en) 2013-03-15 2023-09-26 Nusirt Sciences, Inc. Leucine and nicotinic acid reduces lipid levels
KR20160119863A (ko) 2014-02-27 2016-10-14 뉴서트 사이언시스, 인크. 간 지방증의 감소 또는 예방을 위한 조성물 및 방법
US10442761B2 (en) 2016-02-16 2019-10-15 Concert Pharmaceuticals, Inc. Deuterated GFT-505
US12104209B2 (en) 2016-03-30 2024-10-01 Genfit Non-invasive diagnostic of non-alcoholic steatohepatitis
MX2018012663A (es) * 2016-04-16 2019-07-08 Univ Florida Metodos para aumentar la capacidad de actividad biológica del virus adenoasociado recombinante producido mediante el sistema baculovirus.
CN108658908B (zh) * 2017-07-31 2019-05-10 广州必贝特医药技术有限公司 1，3-二取代烯酮类化合物及其应用
CN109316601B (zh) * 2017-07-31 2021-11-09 武汉朗来科技发展有限公司 药物组合物及其用途
EP3719010B1 (en) 2017-11-30 2023-07-26 Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Aromatic compound, pharmaceutical composition thereof and use thereof
EP3830070A1 (en) 2018-08-03 2021-06-09 Genfit Elafibranor salts
US11634387B2 (en) 2019-09-26 2023-04-25 Abionyx Pharma Sa Compounds useful for treating liver diseases
BR112022015807A2 (pt) 2020-02-10 2023-03-14 Genfit Polimorfos de elafibranor
US20260041661A1 (en) * 2022-08-02 2026-02-12 J2H Biotech Inc. Three-component prodrug, pharmaceutical composition thereof, and medical use thereof

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3558612A (en) * 1968-05-22 1971-01-26 Dow Chemical Co Substituted phenoxyacetic acids
CH593224A5 (pl) * 1973-10-30 1977-11-30 Taisho Pharmaceutical Co Ltd
US3994955A (en) * 1975-01-20 1976-11-30 G. D. Searle & Co. Substituted phenoxydialkylacetic acids and esters
JPS5278856A (en) * 1975-12-26 1977-07-02 Taisho Pharmaceut Co Ltd Preparation of chalcone ethers
US4190671A (en) * 1977-03-17 1980-02-26 Biorex Laboratories Limited Chalcone derivatives
JPS5419947A (en) * 1977-07-16 1979-02-15 Taisho Pharmaceut Co Ltd Chalcone derivatives
US4163859A (en) * 1977-07-18 1979-08-07 G. D. Searle & Co. Phenoxyldialkyl acetic acids and esters
GB8426424D0 (en) * 1984-10-19 1984-11-28 Biorex Laboratories Ltd Chalcone derivatives
JPS6310720A (ja) * 1986-07-01 1988-01-18 Nippon Kayaku Co Ltd ５−リポキシゲナ−ゼ阻害剤および抗アレルギ−剤
JPH023670A (ja) 1988-06-22 1990-01-09 Nippon Oil & Fats Co Ltd アルキルチオカルコン誘導体
JPH0742227B2 (ja) * 1988-11-25 1995-05-10 日本ハイポックス 腎臓疾患治療剤
US5731454A (en) * 1990-02-12 1998-03-24 Virginia Commonwealth University Allosteric modifiers of hemoglobin useful for decreasing oxygen affinity and preserving oxygen carrying capability of stored blood
US5705521A (en) * 1990-02-12 1998-01-06 The Center For Innovative Technology Use of allosteric hemoglobin modifiers in combination with radiation therapy to treat carcinogenic tumors
JPH0442229A (ja) * 1990-06-08 1992-02-12 Fujitsu Ltd レジスト材料およびパターンの形成方法
JPH05255655A (ja) * 1992-03-12 1993-10-05 Kanebo Ltd 紫外線吸収剤
JPH06122623A (ja) * 1992-10-09 1994-05-06 Minofuaagen Seiyaku Honpo:Goushi 抗腫瘍剤
US5276058A (en) * 1993-06-09 1994-01-04 Nippon Hypox Laboratories Incorporated 3,4-dihydroxychalcone derivatives
US5455270A (en) * 1993-08-11 1995-10-03 Bristol-Myers Squibb Co. Stabilized solutions of platinum(II) antitumor agents
DE4327365A1 (de) * 1993-08-14 1995-02-16 Boehringer Mannheim Gmbh Verwendung von Phenolen und Phenolderivaten als Arzneimittel mit fibrinogensenkender Wirkung
US5523302A (en) * 1993-11-24 1996-06-04 The Du Pont Merck Pharmaceutical Company Aromatic compounds containing basic and acidic termini useful as fibrinogen receptor antagonists
WO1998027970A2 (en) 1996-12-24 1998-07-02 National Research Council Of Canada Treatment of diseases or prevention of cellular damage caused by oxygen-containing free radicals
EP0947511A1 (en) * 1998-03-30 1999-10-06 F. Hoffmann-La Roche Ag Derivatives of phenoxy acetic acid and of phenoxymethyl tetrazole having antitumor activity
CN1327384A (zh) * 1998-10-20 2001-12-19 韩国科学技术研究院 作为血浆高密度脂蛋白浓度增高剂的生物类黄酮
EP1254658B1 (en) * 2000-01-27 2008-09-24 Takara Bio Inc. Remedies for the treatment of nerve diorders
US6608101B1 (en) * 2000-06-20 2003-08-19 Atherogenics, Inc. 1, 3-bis-(substituted-phenyl)-2-propen-1-ones and their use to treat VCAM-1 mediated disorders
EP1254759B1 (de) 2001-05-03 2009-03-18 Leister Process Technologies Düse zum Schweissen von Kunststoffbahnen oder -folien
FR2841784B1 (fr) 2002-07-08 2007-03-02 Composition a base de derives de 1,3-diphenylprop-2en-1-one substitues, preparation et utilisations
FR2841900B1 (fr) 2002-07-08 2007-03-02 Genfit S A Nouveaux derives de 1,3-diphenylprop-2-en-1-one substitues, preparation et utilisations
FR2857361B1 (fr) * 2003-07-08 2005-09-09 Genfit S A PREPARATION DE DERIVES DE 1,3-DIPHENYPROP-2-¼n-1-one

Also Published As

Publication number Publication date
PT1519908E (pt) 2007-09-04
US20100120909A1 (en) 2010-05-13
JP4907083B2 (ja) 2012-03-28
BR0312399A (pt) 2005-04-12
US8106097B2 (en) 2012-01-31
NO334650B1 (no) 2014-05-05
BRPI0312399B1 (pt) 2020-03-31
FR2841784B1 (fr) 2007-03-02
CN1688532A (zh) 2005-10-26
DK1519908T3 (da) 2007-10-15
NZ538052A (en) 2007-09-28
SI1519908T1 (sl) 2007-08-31
BRPI0312399B8 (pt) 2021-05-25
MXPA05000425A (es) 2005-07-22
WO2004005243A2 (fr) 2004-01-15
PL207707B1 (pl) 2011-01-31
JP2005532386A (ja) 2005-10-27
US20050171149A1 (en) 2005-08-04
US7632870B2 (en) 2009-12-15
IL165454A0 (en) 2006-01-15
ATE364588T1 (de) 2007-07-15
CN1688532B (zh) 2012-07-11
US20120129932A1 (en) 2012-05-24
CY1108051T1 (el) 2013-09-04
CA2490993A1 (fr) 2004-01-15
WO2004005243A3 (fr) 2004-04-22
KR100947907B1 (ko) 2010-03-17
EA012699B1 (ru) 2009-12-30
US8461212B2 (en) 2013-06-11
KR20050019818A (ko) 2005-03-03
DE60314420T2 (de) 2008-02-28
NO20045082L (no) 2004-12-27
IL165454A (en) 2012-12-31
AU2003264699B2 (en) 2009-09-24
EP1519908A2 (fr) 2005-04-06
FR2841784A1 (fr) 2004-01-09
DE60314420D1 (de) 2007-07-26
EP1519908B1 (fr) 2007-06-13
ZA200501081B (en) 2007-04-25
CA2490993C (fr) 2012-09-18
ES2287529T3 (es) 2007-12-16
AU2003264699A1 (en) 2004-01-23
EA200500170A1 (ru) 2005-10-27

Similar Documents

Publication Publication Date Title
PL373465A1 (pl) Kompozycje oparte na podstawionych pochodnych 1,3-difenyloprop-2-en-1-onu
AU2002258066A1 (en) Dermatological and cosmetic compositions
GB0222495D0 (en) Compounds
NO995544L (no) Forbindelser og metoder for inhibering av ekspresjonen av VCAM-1
CY1108274T1 (el) Μακροβιο ομοιαζον με γλυκογονο πεπτιδιο 2 (glp-2) για την θεραπεια γαστρεντερικων ασθενειων και διαταραχων
IL161829A (en) 1,2,4 - thiadiazole derivatives, some of which are novel and pharmaceutical compositions comprising the same for treating disorders mediated by melanocortin receptor modulators
WO2004045557A3 (en) Novel lapachone compounds and methods of use thereof
WO2003020280A3 (en) Compositions and use thereof in the treatment of cancer
MY141528A (en) Anilinopyrazole derivatives useful for the treatment of diabetes
AU5225498A (en) Biaromatic compounds, pharmaceutical and cosmetic compositions containing them and uses thereof
NZ328874A (en) Heterocyclic biaryl compounds and their use in pharmaceutical compositions for treatment of dermatological, rheumatic, respiratory, cardiovascular and ophthalmological disorders
EP1551392A4 (en) NEW LAPACHO COMPOUNDS AND APPLICATION METHOD THEREFOR
IT1312107B1 (it) Glicosaminoglicani aventi peso molecolare medio di 2400 d atti altrattamento della demenza senile
ATE482922T1 (de) Aloe-emodinderivate und deren verwendung in der behandlung von neoplasien
BRPI0415355A (pt) triarilimidazóis
DK1594456T3 (da) Anvendelse af en sammensætning indeholdende vitamin K1-oxid eller et derivat deraf til behandling og/eller forebyggelse af dermatologiske læsioner hos pattedyr
GB2430365B (en) High-purity texaphyrin metal complexes
EP1931735A4 (en) HIGH-purity TEXAPHYRINMETAL COMPLEXES
FI972673A7 (fi) 4,4-(disubstituoitu)sykloheksan-1-oli-monomeereja ja vastaavia yhdiste itä
ATE338543T1 (de) Zusammensetzungen enthaltend eine superoxiddismutase, einen 5-lipoxygenase- inhibitor sowie deren verwendung
MY134920A (en) 5-beta-sapogenin and pseudosapogenin derivatives and their use in the treatment of dementia
UA83988C2 (ru) Моноклональное антидвойное интегриновое антитело, которое специфически связывает человеческие интегрины альфа v бета 3 и альфа v бета 5, фармацевтическая композиция, которая его содержит, и их применение в терапии
MX9708830A (es) Compuestos de tetralin con actividad de resistencia a varios farmacos.